Pharma feed

N
Novartis AG
FirstWord Pharma· 18 Jul 2019

Novartis lifts annual guidance as second-quarter sales top estimates

Headline results for the second quarter: Innovative medicines sales $9.3 billion +5% Sandoz sales $2.4 billion -1% Overall revenue $11.8 billion (forecasts of $11.5 billion) +4% Profit $6.8 billion -12% Note: All changes are versus

  • Sandoz Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Novartis AG
FirstWord Pharma· 18 Jul 2019

Novartis lifts annual guidance as second-quarter sales top estimates

Headline results for the second quarter: Innovative medicines sales $9.3 billion +5% Sandoz sales $2.4 billion -1% Overall revenue $11.8 billion (forecasts of $11.5 billion) +4% Profit $6.8 billion -12% Note: All changes are versus

  • Sandoz Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Novartis AG
FirstWord Pharma· 18 Jul 2019

Novartis lifts annual guidance as second-quarter sales top estimates

Headline results for the second quarter: Innovative medicines sales $9.3 billion +5% Sandoz sales $2.4 billion -1% Overall revenue $11.8 billion (forecasts of $11.5 billion) +4% Profit $6.8 billion -12% Note: All changes are versus

  • Sandoz Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
GlaxoSmithKline PLC
Edb· 18 Jul 2019

Pharma giant GSK opens $130m manufacturing facility in Singapore

A preview of this article is not available. Please click on the headline to read the complete article

  • GlaxoSmithKline PLC
  • Singapore Economic Development Board
  • Business Expansion
  • Press Releases
  • Company Websites
N
Novartis AG
Market Digest· 18 Jul 2019

Novartis CEO sets aside $700 million to settle doctor bribery lawsuit

By using our website, you agree to the use of cookies as described in our cookie policy.

  • Novartis AG
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Merck & Co., Inc.
Pharmaphorum· 18 Jul 2019

Merck gets FDA nod for new antibiotic, but says use with care

The FDA has approved a new triple-drug antibiotic from Merck & Co, but the company and regulator have cautioned it should only be prescribed for last-ditch use. Recarbrio – which based on established antibiotic combination imipenem/cilastatin with Merck’s new beta-lactamase inhibitor relebactam – has been cleared by the FDA for adults with complicated urinary tract infections (cUTI) and complicated intra-abdominal infections (cIAI).

  • Merck & Co., Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
N
Novartis AG
FirstWord Pharma· 18 Jul 2019

Novartis lifts annual guidance as second-quarter sales top estimates

Headline results for the second quarter: Innovative medicines sales $9.3 billion +5% Sandoz sales $2.4 billion -1% Overall revenue $11.8 billion (forecasts of $11.5 billion) +4% Profit $6.8 billion -12% Note: All changes are versus

  • Sandoz Inc
  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
N
Novartis AG
PM Live· 18 Jul 2019

Novartis raises 2019 guidance as new products gather speed

Novartis chief executive Vas Narasimhan has said he thinks the company is going through a new product launch phase that is unprecedented in its history, and that is starting to be felt in its top-line. The Swiss group raised its guidance for 2019 sales and operating profit again today as it posted an 8% increase in revenues to $11.8bn, driven by seven recently-launched products that all posted growth of 25% or more in the quarter.

  • Novartis AG
  • Financial and Business Performance
  • New Offerings
  • News Articles
  • News and Other Websites
Exelixis Inc
Exelixis· 18 Jul 2019

Exelixis Q2 2019 Financial Results Conference Call

Sign up to receive email alerts whenever Exelixis, Inc. posts new information to the site. Just enter your email address and click Sign Up.

  • Exelixis Inc
  • Erie Indemnity Co.
  • Financial and Business Performance
  • Events
  • Company Websites
N
Airbus Corporate Foundation
TelecomLive· 18 Jul 2019

Tech startup Icertis’ valuation crosses $1 bn, joins unicorn club – TelecomLive

Icertis, which provides contract management software to customers like plane maker Airbus and pharma giant Merck, announced the closing of a $115 million Series E round. The financing round was co-led by Greycroft and Premji Invest, the family investment arm of Wipro Chairman and billionaire Azim Premji.

  • Airbus Corporate Foundation
  • Merck & Co., Inc.
  • Icertis Inc
  • Management Changes
  • News Articles
  • News and Other Websites
N
Johnson & Johnson
Citybizlist· 18 Jul 2019

Wexford Innovation Center Opens in Rhode Island

PROVIDENCE, R.I.--(BUSINESS WIRE)--Governor Gina M. Raimondo today joined state and local officials, representatives from Wexford Science and Technology, Brown University, the Cambridge Innovation Center, Johnson & Johnson, and members of the public to officially open the Wexford Innovation Complex.

  • Johnson & Johnson
  • Cambridge Innovation Center
  • Business Expansion
  • News Articles
  • News and Other Websites
N
Amgen, Inc.
FierceBiotech· 18 Jul 2019

Immusoft names former Amgen biologics chief as chief scientific officer

Immusoft has named Robert Hayes as its chief scientific officer. Hayes, the former head of biologics at Amgen, joins the cell therapy startup as it works to move a treatment for mucopolysaccharidosis type I into clinical testing.

  • Immusoft Corp
  • Amgen, Inc.
  • Management Changes
  • Press Releases
  • News and Other Websites
N
Novartis AG
Seeking Alpha· 18 Jul 2019

Novartis Q2 2019 Earnings Preview

Novartis (NYSE:NVS) is scheduled to announce Q2 earnings results on Thursday, July 18th, before market open. The consensus EPS Estimate is $1.23 (-4.7% Y/Y) and the consensus Revenue Estimate is $11.42B (-13.2% Y/Y). Over the last 2 years, nvs has beaten EPS estimates 88% of the time and has beaten revenue estimates 50% of the time.

  • Novartis AG
  • Financial and Business Performance
  • News Articles
  • News and Other Websites
Twitter· 18 Jul 2019

. @JNJNews' net income jumped 42% in Q2 and more for #pharma #marketers to know. #drugprices $JNJ $BAYN #opioidcrisis http://bit.ly/2Gdls0o

Five things for pharma marketers to know: Wednesday, July 17, 2019
Johnson & Johnson’s net income jumped 42% in Q2 to $5.6 billion, despite net sales dropping 1.3% to $20.6 billion. However, shares of J&J fell about 1% in Tuesday trading becaus...
  • Medical Marketing & Media
  • Johnson & Johnson
  • Financial and Business Performance
  • Social Updates
  • Twitter
  • Broad Institute
  • AbbVie Inc
  • New Offerings
  • Social Updates
  • Twitter
  • Broad Institute
  • Bristol-Myers Squibb Co
  • New Offerings
  • Social Updates
  • Twitter
Twitter· 18 Jul 2019

Investors: $EXEL will announce Q2 earnings on 7/31. Learn more: https://t.co/axfcDFMnmn.

Exelixis to Release Second Quarter 2019 Financial Results on Wednesday, July 31, 2019
– Conference Call and Webcast to Follow at 5:00 p.m. EDT / 2:00 p.m. PDT – ALAMEDA, Calif. --(BUSINESS WIRE)--Jul. 17, 2019-- Exelixis, Inc. (NASDAQ: EXEL) announced today that ...
  • Exelixis Inc
  • Financial and Business Performance
  • Social Updates
  • Twitter
N
Grupo Nacional Provincial , S.A.
Reuters· 18 Jul 2019

Deals of the day-Mergers and acquisitions

(Adds GrandVision NV, Takeda Pharmaceutical, Curaleaf Holdings) July 17 (Reuters) - The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Wednesday: ** Dutch optical retailer GrandVision NV said it was approached by EssilorLuxottica SA and HAL Holding NV for a possible transfer of HAL’s majority stake in the company to the French eyewear group.

  • Grupo Nacional Provincial , S.A.
  • Takeda Pharmaceutical Co Ltd
  • GrandVision BV
  • M&A Activities
  • News Articles
  • News and Other Websites
United States Department of Health and Human Services
Loeb· 18 Jul 2019

At a Glance: Decision of the U.S. District Court for the District of Columbia for Merck & Co., Inc., et al. v. United States Department of Health and Human Services

Decision Decision of the U.S. District Court for the District of Columbia: i) confirming that the Department of Health & Human Services has no statutory authority to compel pharmaceutical manufacturers to publish list prices for their products in marketing and promotional activities, and ii) invalidating the final rule compelling this requirement.

  • United States Department of Health and Human Services
  • Merck & Co., Inc.
  • Loeb & Loeb
  • Regulatory and Legal
  • Company Websites
N
Merck & Co., Inc.
Pharmalive· 18 Jul 2019

Merck’s infections drug Recarbrio wins FDA approval

Merck’s treatment for urinary, abdominal infections gets FDA approval July 17 (Reuters) – The U.S. Food and Drug Administration has approved Merck & Co Inc’s combination treatment for complicated forms of urinary tract and abdominal infections, the drugmaker said on Wednesday.

  • Merck & Co., Inc.
  • Regulatory and Legal
  • News Articles
  • News and Other Websites
Merck & Co., Inc.
Bit (ly)· 18 Jul 2019

UPDATED: With looming ‘apocalypse of drug resistance,’ Merck’s combination antibiotic scores FDA approval on two fronts

For years the big trend among dealmakers at the major players has been centered on ratcheting down upfront payments in favor of bigger milestones. Better known as biobucks for some. But with the top 15 companies competing for the kind of “transformative” pacts that can whip up some excitement on Wall Street, with some big biotechs like Regeneron now weighing in as well, cash is king at the high stakes table.

  • Merck & Co., Inc.
  • Bitly Inc
  • Regulatory and Legal
  • Company Websites
AstraZeneca PLC
Bit (ly)· 18 Jul 2019

Inovio axes staffers, cancer program to 'sharpen focus,' save cash

A few months after AstraZeneca’s MedImmune unit walked away from some of its R&D work with the biotech, Inovio Pharmaceuticals is cutting 28% of its workforce and swinging the ax to a cancer program.

  • AstraZeneca PLC
  • Inovio
  • Bitly Inc
  • Procurement and Sales
  • Company Websites
American Chemical Society
Acs (org)· 18 Jul 2019

Needing more viruses, Novartis taps Catalent to boost manufacturing of its new gene therapy Zolgensma

Credit: Paragon Bioservices Novartis is teaming up with the contract manufacturing firm Catalent Biologics to boost production of its recently commercialized gene therapy Zolgensma. The announcement is a surprise because three months ago Novartis’ gene therapy subsidiary, AveXis, said it is buying a facility in Longmont, Colorado, for the same purpose.

  • American Chemical Society
  • Novartis AG
  • Catalent Inc
  • Procurement and Sales
  • Company Websites
Novartis AG
Sandoz· 18 Jul 2019

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +81% (cc) with

  • Sandoz Inc
  • Novartis AG
  • Financial and Business Performance
  • New Offerings
  • Press Releases
  • Company Websites
N
Novartis AG
Globe Newswire· 18 Jul 2019

Novartis delivers strong sales, double digit core operating income growth and launches Zolgensma and Piqray in second quarter; sales and profit guidance increased

Continuing operations[1] net sales up 8% (cc[2], +4% USD) driven by: Cosentyx at USD 858 million, +25% (cc) mainly driven by continued strong US growth (+31%) Entresto grew to USD 421 million, +81% (cc) with

  • Novartis AG
  • Financial and Business Performance
  • New Offerings
  • Press Releases
  • Press Release Agencies
1 2 3 4 5